The ARSB Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population with targeted disruption of the ARSB gene in the human A-549 lung adenocarcinoma cell line. This loss-of-function model provides a versatile tool for studying sulfatase-dependent pathways without clonal selection artifacts. The ready-to-use polyclonal format supports pooled knockout experiments, including high-content screening and population-level phenotypic assays.
The parental A-549 cell line, derived from human lung adenocarcinoma with epithelial morphology, is a widely utilized model for lung cancer research. It recapitulates key adenocarcinoma traits such as deregulated signaling and metastatic potential, and serves as an optimal background for genetic manipulation, enabling detailed functional genomics in a clinically relevant cancer context.
ARSB encodes the lysosomal enzyme arylsulfatase B, which hydrolyzes 4-sulfate groups from N-acetylgalactosamine-4-sulfate residues in dermatan sulfate and chondroitin sulfate. Its expression is regulated by TFEB and inflammatory cytokines (IL-6, TGF-??), and it interacts with substrates and lysosomal membrane proteins LAMP1 and LIMP2. ARSB disruption leads to sulfated glycosaminoglycan accumulation, reducing chondroitin-4-sulfate turnover and dysregulating downstream signaling, including diminished EGFR activation and altered Wnt/??-catenin signaling. This cascade highlights the enzyme??s role in glycosaminoglycan homeostasis and its influence on growth factor?Creceptor interactions.
In the A-549 adenocarcinoma model, ARSB knockout enables investigation of impaired glycosaminoglycan degradation on cancer cell behavior. Accumulated sulfated glycosaminoglycans may modify extracellular matrix interactions and growth factor availability, potentially affecting proliferation, migration, and invasion. The model also mirrors MPS VI pathology in a malignant background, facilitating studies on crosstalk between lysosomal storage defects and oncogenic signaling.
This polyclonal knockout population supports diverse applications, such as dissecting sulfation-dependent EGFR and Wnt/??-catenin signaling via western blot, RT-qPCR, and immunofluorescence. It enables drug screening for lysosomal storage disorders using sulfatase assays and glycosaminoglycan quantification (Alcian blue), as well as functional cancer assays including MTS proliferation and Transwell migration/invasion. The model is also suitable for tumor microenvironment studies with altered glycosaminoglycan profiles. Contact Ascent Research for further information.
